Prioritisation of potential drug targets against Bartonella bacilliformis by an integrative in-silico approach
Farfán-López, Mariella; Espinoza-Culupú, Abraham; García-de-la-Guarda, Ruth; Serral, Federico; Sosa, Ezequiel; Palomino, María Mercedes; Porto, Darío A Fernández Do.
Mem Inst Oswaldo Cruz, v. 115, e200184, jul. 2020
Artículo
en Inglés
| SES-SP, SESSP-IBPROD, SES-SP | ID: bud-3184
BACKGROUND:
Carrion’s disease (CD) is a neglected biphasic illness caused by Bartonella bacilliformis, a Gram-negative bacteria found in the Andean valleys. The spread of resistant strains underlines the need for novel antimicrobials against B. bacilliformis and related bacterial pathogens.OBJECTIVE:
The main aim of this study was to integrate genomic-scale data to shortlist a set of proteins that could serve as attractive targets for new antimicrobial discovery to combat B. bacilliformis.METHODS:
We performed a multidimensional genomic scale analysis of potential and relevant targets which includes structural druggability, metabolic analysis and essentiality criteria to select proteins with attractive features for drug discovery.FINDINGS:
We shortlisted seventeen relevant proteins to develop new drugs against the causative agent of Carrion’s disease. Particularly, the protein products of fabI, folA, aroA, trmFO, uppP and murE genes, meet an important number of desirable features that make them attractive targets for new drug development. This data compendium is freely available as a web server (http//target.sbg.qb.fcen.uba.ar/). MAINCONCLUSION:
This work represents an effort to reduce the costs in the first phases of B. bacilliformis drug discovery.
Biblioteca responsable:
BR78.1
Texto completo
Documentos relacionados